NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 403
- Registration Number
- NCT00170976
- Locations
- 🇩🇪
Sites in germany, Multiple Locations, Germany
🇨🇭Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 67
- Registration Number
- NCT00171795
Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 213
- Registration Number
- NCT00171327
- Locations
- 🇷🇺
Novartis, Moscow, Russian Federation
Valsartan/Hydrochlorothiazide Combination in Hypertensive Patients Not Controlled With Valsartan Alone
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2714
- Registration Number
- NCT00170989
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 317
- Registration Number
- NCT00170924
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Comparison of Two Treatment Strategies in Hypertensive Patients
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 4445
- Registration Number
- NCT00171444
Efficacy and Safety of Valsartan/Amlodipine Combination in Patients With Severe Hypertension
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 130
- Registration Number
- NCT00171535
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 84
- Registration Number
- NCT00171236
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Antialbuminuric Effects of Valsartan and Lisinopril
Phase 4
Terminated
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 54
- Registration Number
- NCT00171600
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-11-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 83
- Registration Number
- NCT00171288
- Locations
- 🇪🇸
Novartis, Madrid, Spain
© Copyright 2024. All Rights Reserved by MedPath